Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

NASDAQ:EVOK opened at $4.71 on Friday. The company has a 50-day moving average of $5.00 and a 200-day moving average of $5.33. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $15.13. The company has a market capitalization of $7.02 million, a price-to-earnings ratio of -0.43 and a beta of 0.16.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent reporting period.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.